Karyopharm Therapeutics
KPTI
89 hedge funds and large institutions have $248M invested in Karyopharm Therapeutics in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 13 closing their positions.
330% more call options, than puts
Call options by funds: $9.77M | Put options by funds: $2.27M
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
0% more funds holding
Funds holding: 89 → 89 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
59% less capital invested
Capital invested by funds: $610M → $248M (-$362M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$24.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$16.2M |
| 3 |
Millennium Management
New York
|
+$11.8M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7.88M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$2.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$22.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$16.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.74M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$4.8M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$2.68M |
KPTI Hedge Fund Activity: Q3 2015 in Review
89 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2015, worth a combined $248M — down 59% from $610M a quarter earlier.
Fund positioning in KPTI was balanced in Q3 2015: 13 funds opened new positions, 13 closed out, 37 added to existing stakes and 25 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $24.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $22.4M sold.
- 89 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $248M of Karyopharm Therapeutics stock for Q3 2015, down 59% quarter-over-quarter.
- 13 funds opened new Karyopharm Therapeutics positions in Q3 2015 and 13 closed out, a net change of 0 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2015 was Palo Alto Investors, an estimated $24.1M added.
- The largest Karyopharm Therapeutics seller in Q3 2015 was PFM Health Sciences, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2015.